vs
美森（MATX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
美森的季度营收约是Revvity的1.1倍（$851.9M vs $772.1M），美森净利率更高（16.8% vs 12.7%，领先4.1%），Revvity同比增速更快（5.9% vs -4.3%），Revvity自由现金流更多（$161.8M vs $42.2M），过去两年Revvity的营收复合增速更高（9.0% vs 8.6%）
美森公司（Matson, Inc.）是美国知名航运服务企业，总部位于夏威夷州火奴鲁鲁，成立于1882年。旗下子公司美森航运主营跨太平洋海运业务，服务覆盖夏威夷、阿拉斯加、关岛、密克罗尼西亚、太平洋诸岛、中国及日本等地区。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MATX vs RVTY — 直观对比
营收规模更大
MATX
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出10.2%
-4.3%
净利率更高
MATX
高出4.1%
12.7%
自由现金流更多
RVTY
多$119.6M
$42.2M
两年增速更快
RVTY
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $851.9M | $772.1M |
| 净利润 | $143.1M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 16.9% | 14.5% |
| 净利率 | 16.8% | 12.7% |
| 营收同比 | -4.3% | 5.9% |
| 净利润同比 | 11.8% | 3.9% |
| 每股收益（稀释后） | $4.47 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATXRVTY
| Q4 25 | $851.9M | $772.1M | ||
| Q3 25 | $880.1M | $698.9M | ||
| Q2 25 | $830.5M | $720.3M | ||
| Q1 25 | $782.0M | $664.8M | ||
| Q4 24 | $890.3M | $729.4M | ||
| Q3 24 | $962.0M | $684.0M | ||
| Q2 24 | $847.4M | $691.7M | ||
| Q1 24 | $722.1M | $649.9M |
净利润MATXRVTY
| Q4 25 | $143.1M | $98.4M | ||
| Q3 25 | $134.7M | $46.7M | ||
| Q2 25 | $94.7M | $53.9M | ||
| Q1 25 | $72.3M | $42.2M | ||
| Q4 24 | $128.0M | $94.6M | ||
| Q3 24 | $199.1M | $94.4M | ||
| Q2 24 | $113.2M | $55.4M | ||
| Q1 24 | $36.1M | $26.0M |
毛利率MATXRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率MATXRVTY
| Q4 25 | 16.9% | 14.5% | ||
| Q3 25 | 18.3% | 11.7% | ||
| Q2 25 | 13.6% | 12.6% | ||
| Q1 25 | 10.5% | 10.9% | ||
| Q4 24 | 16.6% | 16.3% | ||
| Q3 24 | 25.2% | 14.3% | ||
| Q2 24 | 14.7% | 12.4% | ||
| Q1 24 | 5.1% | 6.8% |
净利率MATXRVTY
| Q4 25 | 16.8% | 12.7% | ||
| Q3 25 | 15.3% | 6.7% | ||
| Q2 25 | 11.4% | 7.5% | ||
| Q1 25 | 9.2% | 6.4% | ||
| Q4 24 | 14.4% | 13.0% | ||
| Q3 24 | 20.7% | 13.8% | ||
| Q2 24 | 13.4% | 8.0% | ||
| Q1 24 | 5.0% | 4.0% |
每股收益（稀释后）MATXRVTY
| Q4 25 | $4.47 | $0.86 | ||
| Q3 25 | $4.24 | $0.40 | ||
| Q2 25 | $2.92 | $0.46 | ||
| Q1 25 | $2.18 | $0.35 | ||
| Q4 24 | $3.69 | $0.77 | ||
| Q3 24 | $5.89 | $0.77 | ||
| Q2 24 | $3.31 | $0.45 | ||
| Q1 24 | $1.04 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $141.9M | $919.9M |
| 总债务越低越好 | $361.2M | — |
| 股东权益账面价值 | $2.8B | $7.3B |
| 总资产 | $4.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.13× | — |
8季度趋势，按日历期对齐
现金及短期投资MATXRVTY
| Q4 25 | $141.9M | $919.9M | ||
| Q3 25 | $92.7M | $931.4M | ||
| Q2 25 | $59.1M | $991.8M | ||
| Q1 25 | $122.0M | $1.1B | ||
| Q4 24 | $266.8M | $1.2B | ||
| Q3 24 | $270.3M | $1.2B | ||
| Q2 24 | $168.2M | $2.0B | ||
| Q1 24 | $25.9M | $1.7B |
总债务MATXRVTY
| Q4 25 | $361.2M | — | ||
| Q3 25 | $370.9M | — | ||
| Q2 25 | $341.3M | — | ||
| Q1 25 | $351.1M | — | ||
| Q4 24 | $361.2M | — | ||
| Q3 24 | $370.9M | — | ||
| Q2 24 | $381.0M | — | ||
| Q1 24 | $390.8M | — |
股东权益MATXRVTY
| Q4 25 | $2.8B | $7.3B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.6B | $7.6B | ||
| Q4 24 | $2.7B | $7.7B | ||
| Q3 24 | $2.6B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.4B | $7.8B |
总资产MATXRVTY
| Q4 25 | $4.6B | $12.2B | ||
| Q3 25 | $4.6B | $12.1B | ||
| Q2 25 | $4.5B | $12.4B | ||
| Q1 25 | $4.5B | $12.4B | ||
| Q4 24 | $4.6B | $12.4B | ||
| Q3 24 | $4.4B | $12.8B | ||
| Q2 24 | $4.3B | $13.4B | ||
| Q1 24 | $4.2B | $13.4B |
负债/权益比MATXRVTY
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $176.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $42.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 5.0% | 21.0% |
| 资本支出强度资本支出/营收 | 15.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.24× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $153.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MATXRVTY
| Q4 25 | $176.9M | $182.0M | ||
| Q3 25 | $175.6M | $138.5M | ||
| Q2 25 | $105.6M | $134.3M | ||
| Q1 25 | $89.0M | $128.2M | ||
| Q4 24 | $174.7M | $174.2M | ||
| Q3 24 | $248.6M | $147.9M | ||
| Q2 24 | $307.9M | $158.6M | ||
| Q1 24 | $36.6M | $147.6M |
自由现金流MATXRVTY
| Q4 25 | $42.2M | $161.8M | ||
| Q3 25 | $92.4M | $120.0M | ||
| Q2 25 | $19.3M | $115.5M | ||
| Q1 25 | $-200.0K | $112.2M | ||
| Q4 24 | $49.3M | $149.8M | ||
| Q3 24 | $189.0M | $125.6M | ||
| Q2 24 | $238.1M | $136.6M | ||
| Q1 24 | $-18.7M | $129.7M |
自由现金流率MATXRVTY
| Q4 25 | 5.0% | 21.0% | ||
| Q3 25 | 10.5% | 17.2% | ||
| Q2 25 | 2.3% | 16.0% | ||
| Q1 25 | -0.0% | 16.9% | ||
| Q4 24 | 5.5% | 20.5% | ||
| Q3 24 | 19.6% | 18.4% | ||
| Q2 24 | 28.1% | 19.7% | ||
| Q1 24 | -2.6% | 20.0% |
资本支出强度MATXRVTY
| Q4 25 | 15.8% | 2.6% | ||
| Q3 25 | 9.5% | 2.6% | ||
| Q2 25 | 10.4% | 2.6% | ||
| Q1 25 | 11.4% | 2.4% | ||
| Q4 24 | 14.1% | 3.4% | ||
| Q3 24 | 6.2% | 3.3% | ||
| Q2 24 | 8.2% | 3.2% | ||
| Q1 24 | 7.7% | 2.7% |
现金转化率MATXRVTY
| Q4 25 | 1.24× | 1.85× | ||
| Q3 25 | 1.30× | 2.97× | ||
| Q2 25 | 1.12× | 2.49× | ||
| Q1 25 | 1.23× | 3.03× | ||
| Q4 24 | 1.36× | 1.84× | ||
| Q3 24 | 1.25× | 1.57× | ||
| Q2 24 | 2.72× | 2.87× | ||
| Q1 24 | 1.01× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MATX
| Ocean Transportation Segment | $704.2M | 83% |
| Logistics Services Segment | $147.7M | 17% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
